Clinical Trial Update: Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating regorafenib in combination with nivolumab for colorectal cancer (proficient mismatch repair and microsatellite stable). The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)
• nivolumab (nivolumab)

Snippet

Sponsor: Bayer | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-12-14